Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04802252
Other study ID # SFUYIN-04
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 1, 2021
Est. completion date June 1, 2022

Study information

Verified date March 2021
Source Qianfoshan Hospital
Contact Lucheng Song, Doctor
Phone +8613589089003
Email lucheng.s@163.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Pulse diagnosis is one of the traditional diagnostic methods of traditional Chinese medicine, which is of great significance in the process of disease diagnosis.Pulse diagnosis is the diagnosis of disease by touching the pulse of the radial artery at the wrist. Different diseases reflect different pulse characteristics.What we've found in long-term clinical observation is that patients with benign prostatic hyperplasia have something different in their pulse,the abnormal pulse we called "astringent pulse".There is no modern physiologic and pathological description on the occurrence of "astringent pulse" in traditional pulse science, so we study it from acoustics perspective.Our team thinks that every beat of the heart produces a vibration, which produces sound waves,the sound waves travel through the blood and eventually reflect off the arterial walls.When an organ(such as the prostate),develops hyperplasia, local blood flow changes,the flow of blood, which should be laminar, changes and becomes turbulent,the conduction of sound waves in turbulence is disordered,so we end up with pulse features that are different from normal people that are reflected on the arterial wall. We have previously studied the pulse characteristics of chronic gastritis, coronary heart disease, cirrhosis and some other diseases,different pulse sounds were collected and analyzed using an independently developed Acoustic Pulse Detection System,the ideal results have been obtained.We found that most of the abnormal sound waves were between 20Hz and 500Hz, so we classified this sound wave as low frequency and audible sound wave.Based on the above analysis, this study will use the acoustic pulse detection system to collect the pulse images of patients with benign prostatic hyperplasia(BPH).We expected to collect the pulse waves of 62 patients and 62 relatively healthy people without BPH, and use Fourier transform, wavelet analysis and other analysis methods to study the characteristics of the collected sound waves, and observe the pulse characteristics of BPH disease.Then diagnostic tests were carried out to calculate the sensitivity and specificity of the acoustic pulse detection system in the diagnosis of BPH. This experiment will further verify the effectiveness of pulse diagnosis of diseases, and finally lay a foundation for the development of pulse diagnostic instrument can diagnose a variety of diseases.


Recruitment information / eligibility

Status Recruiting
Enrollment 124
Est. completion date June 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 50 Years to 80 Years
Eligibility Inclusion Criteria: Test group: 1. From March 2020 to June 2021, patients of Chinese Medicine outpatient department, ward and physical examination were continuously recruited in the First Affiliated Hospital of Shandong First Medical University; 2. Research site: The First Affiliated Hospital of Shandong First Medical University; 3. Comprehensive evaluation of symptoms, signs and ultrasound examination, meeting the diagnostic criteria of BPH in middle-aged and elderly male patients; 4. Ages ranged from 50 to 80 years, and vital signs were stable; 5. Patients with informed consent to accept this pulse collection; Control group: 1. From March 2020 to June 2021, patients of Chinese Medicine outpatient department, ward and physical examination were continuously recruited in the First Affiliated Hospital of Shandong First Medical University ; 2. Research site: The First Affiliated Hospital of Shandong First Medical University; 3. Symptoms, signs and ultrasonography were evaluated comprehensively, and middle-aged and elderly men with BPH disease were clearly excluded; 4. Ages ranged from 50 to 80 years, and vital signs were stable; 5. Patients with informed consent to accept this pulse collection; Exclusion Criteria: Test group: 1. Those who have a serious illness and sit for less than 10 minutes in a quiet state; 2. Symptoms, signs and ultrasonography were evaluated comprehensively, and middle-aged and elderly men with BPH disease were clearly excluded; 3. Patients with severe infectious diseases; 4. Fanguan pulse, oblique flying pulse, etc. who are not easy to collect pulse; 5. Those who have incomplete information due to subjective or objective reasons that affect the result judgment; 6. Patients with Parkinson's or other limb tremors; 7. Those who has not signed an informed consent form; 8. Patients with atrial fibrillation. Control group: 1. Those who have a serious illness and sit for less than 10 minutes in a quiet state; 2. Comprehensive evaluation of symptoms, signs and ultrasound examination, meeting the diagnostic criteria of BPH in middle-aged and elderly male patients; 3. Patients with severe infectious diseases; 4. Fanguan pulse, oblique flying pulse, etc. who are not easy to collect pulse; 5. Those who have incomplete information due to subjective or objective reasons that affect the result judgment; 6. Patients with Parkinson's or other limb tremors; 7. Those who has not signed an informed consent form; 8. Patients with atrial fibrillation.

Study Design


Locations

Country Name City State
China Qianfoshan Hospital, The First Hospital affiliated of Shandong First Medical University Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Qianfoshan Hospital

Country where clinical trial is conducted

China, 

References & Publications (8)

Bilton K, Hammer L, Zaslawski C. Contemporary Chinese pulse diagnosis: a modern interpretation of an ancient and traditional method. J Acupunct Meridian Stud. 2013 Oct;6(5):227-33. doi: 10.1016/j.jams.2013.04.002. Epub 2013 Apr 24. Review. — View Citation

Descazeaud A, Robert G, Delongchamps NB, Cornu JN, Saussine C, Haillot O, Devonec M, Fourmarier M, Ballereau C, Lukacs B, Dumonceau O, Azzouzi AR, Faix A, Desgrandchamps F, de la Taille A; Comité des troubles mictionnels de l'homme de l'association française d'urologie. [Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association]. Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6. French. — View Citation

Egan KB. The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016 Aug;43(3):289-97. doi: 10.1016/j.ucl.2016.04.001. Review. — View Citation

Foo KT. What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)? World J Urol. 2019 Jul;37(7):1293-1296. doi: 10.1007/s00345-019-02691-0. Epub 2019 Feb 25. Review. — View Citation

Lima CB, Angrimani DSR, Flores RB, Vannucchi CI. Endocrine, prostatic vascular, and proapoptotic changes in dogs with benign prostatic hyperplasia treated medically or surgically. Domest Anim Endocrinol. 2021 Apr;75:106601. doi: 10.1016/j.domaniend.2020.106601. Epub 2020 Nov 23. — View Citation

Thaler L, Goodale MA. Echolocation in humans: an overview. Wiley Interdiscip Rev Cogn Sci. 2016 Nov;7(6):382-393. doi: 10.1002/wcs.1408. Epub 2016 Aug 19. Review. — View Citation

Van Asseldonk B, Barkin J, Elterman DS. Medical therapy for benign prostatic hyperplasia: a review. Can J Urol. 2015 Oct;22 Suppl 1:7-17. Review. — View Citation

Wang D, Zhang D, Lu G. An Optimal Pulse System Design by Multichannel Sensors Fusion. IEEE J Biomed Health Inform. 2016 Mar;20(2):450-9. doi: 10.1109/JBHI.2015.2392132. Epub 2015 Jan 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The characteristic sound waves extracted from radial artery of patients with benign prostatic hyperplasia and relatively healthy men without benign prostatic hyperplasia are distinguished. This characteristic sound wave can distinguish patients with benign prostatic hyperplasia from relatively healthy men without benign prostatic hyperplasia. 30 minutes
See also
  Status Clinical Trial Phase
Recruiting NCT04807296 - Thulium Fiber Laser Enucleation of the Prostate (TFLEP) vs HoLEP With Moses Technology (m-HoLEP) N/A
Recruiting NCT05574244 - Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction N/A
Recruiting NCT04288427 - 5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy N/A
Not yet recruiting NCT04245566 - Prostatic Artery Embolization vs. Pharmacotherapy for LUTS/BPH Phase 3
Completed NCT02509975 - Safety and Efficacy of OCL 503 in Prostate Artery Embolization N/A
Completed NCT03246880 - Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients Phase 3
Withdrawn NCT01967251 - Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction Phase 2
Completed NCT02206243 - Embozene® Microspheres for Prostatic Arterial Embolization in Patients With Symptomatic Benign Prostatic Hyperplasia
Completed NCT02283684 - GreenLight Laser Photoselective Vaporization of the Prostate vs Bipolar Transurethral Vaporization of the Prostate; RCT Phase 4
Completed NCT01454349 - Study of PRX302 for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia (BPH) Phase 1/Phase 2
Completed NCT01438775 - Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) Phase 3
Completed NCT01139762 - A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms Phase 3
Completed NCT01152190 - A Study in Benign Prostatic Hyperplasia Phase 3
Active, not recruiting NCT00400894 - Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma N/A
Completed NCT00224133 - The Evaluation of the Safety of a New Drug for Benign Prostatic Hyperplasia Used for 9 Months Phase 3
Completed NCT00701779 - Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Phase 4
Unknown status NCT00381108 - Study of the Effects of Pomegranate Tablets on Enlarged Prostates Phase 1
Terminated NCT02962674 - To Evaluate the Safety and Performance of the ProstaCare Water Electrolysis System in Relieving Symptoms of BPH. N/A
Active, not recruiting NCT05415748 - Deprescribing Tamsulosin in Older Men Phase 4
Recruiting NCT04853914 - Evaluation of the Safety of the Treatment of Benign Prostatic Hyperplasia by High Intensity Focused Ultrasound. N/A